First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study.
Thomas Bardol, Zahra Eslami-S, Doryan Masmoudi...
https://pubmed.ncbi.nlm.nih.gov/38132919Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID04025541
Analysis of Circulating Tumor Markers in Blood for Various Cancers with Multiple Patient Cohorts
Led by Institut du Cancer de Montpellier - Val d'Aurelle · Updated on 2025-04-02
992
Participants Needed
2
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying circulating tumor biomarkers in blood to improve cancer diagnosis, prognosis, and treatment monitoring. This research focuses on using blood tests as a less invasive alternative to tumor biopsies, which may help detect mutations and study resistance mechanisms. The study explores how medical interventions like chemotherapy, biopsies, or surgeries affect the release of these markers into the bloodstream. The study includes various patient groups with different types of cancers such as breast, lung, colon, glioma, and sarcoma. Participants undergo blood sampling at multiple key time points, including before treatment, during treatment cycles, follow-up visits, and at disease progression. Each cohort follows specific blood collection schedules tailored to their treatment type to assess tumor markers and related biological factors. Participants will provide blood samples at prescribed intervals depending on their cancer type and treatment plan. Researchers will analyze these samples to evaluate the feasibility of different tumor biomarker tests and their potential clinical utility. The study monitors patients over several years, assessing treatment responses, toxicities, and correlations between blood markers and disease progression to better understand biomarker roles in cancer management.
CONDITIONS
Brief Title
Analysis of Circulating Tumor Markers in Blood
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patient with confirmed or suspected invasive tumor of any location or stage
- Male or female aged 18 years or older
- Signed informed consent obtained before any study procedure
You will not qualify if you...
- Individuals under guardianship or deprived of freedom
- Inability to have regular medical follow-up due to psychological, family, social, or geographical reasons
- Pregnant or breastfeeding women
- Patients not affiliated with a Social Protection System
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - Up to 4 years depending on cohort assignment
Participants undergo blood sampling at various key time points to analyze circulating tumor markers. The timing and frequency of blood samples vary by cohort and clinical situation.
Multiple blood sampling visits at baseline, during treatment cycles, at response assessments, and at progression or follow-up
Trial Site Locations
Total: 2 locations
1
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France, 34298
Actively Recruiting
2
ICM
Montpellier, France, 34298
Actively Recruiting
Loading map...
Research Team
T
texier emmannuelle
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
13
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects.
Fanny Leenhardt, Frédéric Fiteni, Ludovic Gauthier...
https://pubmed.ncbi.nlm.nih.gov/35456675Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy.
Fanny Leenhardt, Marie Alexandre, Severine Guiu...
https://pubmed.ncbi.nlm.nih.gov/34286354Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction.
Fanny Leenhardt, Matthieu Gracia, Catherine Perrin...
https://pubmed.ncbi.nlm.nih.gov/32623316